EUVIMEDEUVIMED entdecken
Open Access

Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials

Michael E Roth iD, Susan K Parsons, Patricia A Ganz iD, Lynne I Wagner iD, Pamela S Hinds, Sarah Alexander, Kristin Bingen, Sharon L Bober, Julienne Brackett, David Cella, N Lynn Henry, Daniel J Indelicato und 7 weitere

JNCI: Journal of the National Cancer Institute · 2023

DOI: 10.1093/jnci/djac166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2023. Verfasst von Michael E Roth und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatrics and Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials as Topic, Patient Reported Outcome Measures. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disparities in care, treatment-related toxicity and health-related quality of life (HRQoL) for adolescents and young adults (AYAs, aged 15-39 years) with cancer are under-addressed partly because of limited collection of patient-reported outcomes (PROs) in cancer clinical trials (CCTs). The AYA years include key developmental milestones distinct from younger and older patients, and cancer interrupts attainment of critical life goals. Lack of consensus on a standardized approach to assess HRQoL and treatment-related toxicity in AYA CCTs has limited the ability to improve patient outcomes. The National Cancer Institute’s Clinical Trials Network AYA PRO Task Force was assembled to reach consensus on a core set of PROs and foster its integration into AYA CCTs. Eight key considerations for selecting the core PRO AYA battery components were identified: relevance to AYAs; importance of constructs across the age continuum; prioritization of validated measures; availability of measures without licensing fees; availability in multiple languages; applicability to different cancer types and treatments; ability to measure different HRQoL domains and toxicities; and minimized burden on patients and sites. The Task Force used a modified Delphi approach to identify key components of the PRO battery. The Patient-Reported Outcomes Measurement Information System (PROMIS) and the PRO Common Terminology Criteria for Adverse Events Measurement System met all criteria and were selected to assess HRQoL and treatment toxicity, respectively. Investigators are rapidly incorporating the recommendations of the Task Force into AYA trials. Inclusion of a standardized assessment of HRQoL and treatment toxicities in AYA CCTs is a vital first step to develop interventions to improve health outcomes for AYAs diagnosed with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsClinical Trials as TopicPatient Reported Outcome MeasuresAdolescentHumansYoung AdultQuality of LifeAdultHealthcare DisparitiesAntineoplastic Agents

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Pediatrics and Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Medicine, Division of Hematology/Oncology, Tufts Medical Center, and the Tufts University School of Medicine, Boston, MA, USA.
  • Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Department of Social Sciences and Health Policy, Wake Forest School of Medicine and the Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, USA.
  • Department of Nursing Science, Children's National Hospital, George Washington University School of Medicine, Washington, DC, USA.
  • Division of Haematology/Oncology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Michael E Roth, Patricia A Ganz, Lynne I Wagner, Gita Thanarajasingam, Bryce B Reeve, John M Salsman

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Roth, M. E., Parsons, S. K., Ganz, P. A., Wagner, L. I., Hinds, P. S., Alexander, S., Bingen, K., Bober, S. L., Brackett, J., Cella, D., Henry, N. L., Indelicato, D. J., Johnson, R. H., Miller, T. P., Rosenberg, S. M., Schmitz, K. H., Thanarajasingam, G., Reeve, B. B., & Salsman, J. M. (2023). Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djac166

Vancouver

Roth ME, Parsons SK, Ganz PA, Wagner LI, Hinds PS, Alexander S, et al. Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials. JNCI: Journal of the National Cancer Institute. 2023. doi:10.1093/jnci/djac166

BibTeX
@article{Roth2023,
  author = {Roth, Michael E and Parsons, Susan K and Ganz, Patricia A and Wagner, Lynne I and Hinds, Pamela S and Alexander, Sarah and Bingen, Kristin and Bober, Sharon L and Brackett, Julienne and Cella, David and Henry, N Lynn and Indelicato, Daniel J and Johnson, Rebecca H and Miller, Tamara P and Rosenberg, Shoshana M and Schmitz, Kathryn H and Thanarajasingam, Gita and Reeve, Bryce B and Salsman, John M},
  title = {Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2023},
  doi = {10.1093/jnci/djac166}
}
Kostenlos starten →